The effect of naproxen patches on relieving orthodontic pain by evaluation of VAS and IL-1β inflammatory factor: a split-mouth study

Ladan Eslamian¹, Maryam Torshabi², Saeed Reza Motamedian³, Yasamin Babaee Hemmati⁴, Seyed Alireza Mortazavi⁵

Introduction: Pain related to orthodontic tooth movement is common and cause dissatisfaction and discomfort. Objective: The present study aimed to compare the efficacy of naproxen patches in pain control during orthodontic tooth separation, by means of visual analogue scale (VAS) and interleukin 1β (IL-1β) levels in gingival crevicular fluid (GCF). Methods: In this split-mouth triple-blind clinical trial, with 40 patients following separation, 5% naproxen or placebo patches were randomly placed on the upper right or left first molars every 8 hours. Pain intensity scores were determined after 2 and 6 hours, sleep time, 24 hours, days 2, 3 and 7 by the patients using a 100-mm VAS ruler. IL-1β levels in GCF were evaluated by ELISA at baseline, 1 and 24 hours and 7 days. Paired samples t-tests and two-way repeated measures ANOVA analysis of variance with a significance level of 0.05 were applied. Results: A total number of 30 patients (13 males and 17 females) finished the trial. Significant differences were found in pain scores (p<0.0001) and IL-1β levels (p=0.047) between naproxen and placebo groups. Lower pain scores were reported for the patients using naproxen patches at all time points, except 1 hour after separation. IL-1β levels were lower for the patients using naproxen patches only 1 hour after separation (p=0.047). The peak of pain scores and IL-1β levels were calculated at 24 hours. Conclusion: In the light of VAS scores and IL-1β levels, naproxen patches reduced the pain caused by separator placement.

Keywords: Pain management. Non-steroidal anti-inflammatory agents. Visual analog scale. Interleukin-1 beta.

Introdução: a dor relacionada à movimentação dentária ortodôntica é comum e causa insatisfação e desconforto. Objetivo: o presente estudo teve como objetivo avaliar a eficácia de curativos de naproxeno no controle da dor durante a separação ortodôntica dos dentes, por meio de escalas visuais analógicas (EVA) e dos níveis de interleucina 1β (IL-1β) no fluido crevicular gengival (FCG). Métodos: neste ensaio clínico, triplo-cego, boca dividida, com 40 pacientes após a separação dos dentes, foram aplicados, de forma aleatória, curativos com naproxeno a 5% ou placebo, nos primeiros molares superiores, direito ou esquerdo, a cada 8 horas. Os escores de intensidade da dor foram registrados pelos pacientes após 2 e 6 horas, durante o sono, após 24 horas, 2, 3 e 7 dias, usando uma EVA de 100 mm. Os níveis de IL-1β no FCG foram avaliados pelo ELISA no momento inicial, e após 1 e 24 horas e 7 dias. Foram aplicados testes t para amostras pareadas e ANOVA de duas vias para medidas repetidas, com nível de significância de 0,05. Resultados: no total, 30 pacientes (13 homens e 17 mulheres) terminaram o ensaio clínico. Diferenças significativas foram encontradas nos escores de dor (p<0,0001) e níveis de IL-1β (p=0,047) entre os grupos naproxeno e placebo. Índices mais baixos de dor foram relatados pelos pacientes que usaram curativos de naproxeno em todos os tempos avaliados, com exceção de 1 hora após a separação. Os níveis de IL-1β foram menores nos pacientes que usaram os curativos de naproxeno apenas 1 hora após a separação (p=0,047). Os picos dos escores de dor e dos níveis de IL-1β foram registrados 24 horas após a separação. Conclusão: considerando-se os escores das EVAs e os níveis de IL-1β, pode-se concluir que os curativos de naproxeno reduziram a dor causada pela instalação dos separadores ortodônticos.

Palavras-chave: Controle da dor. Agentes anti-inflamatórios não esteroides. Escala visual analógica. Interleucina-1 beta.

References:
1. Shahid Beheshti University of Medical Sciences, Dentofacial Deformities Research Center, Department of Orthodontics, School of Dentistry (Tehran, Iran).
2. Shahid Beheshti University of Medical Sciences, Dental Biomaterials Department, School of Dentistry (Tehran, Iran).
3. Guilan University of Medical Sciences, Dental Sciences Research Center, Department of Orthodontics, School of Dentistry (Rasht, Iran).
4. Shahid Beheshti University of Medical Sciences, School of Pharmacy (Tehran, Iran).
5. The authors report no commercial, proprietary or financial interest in the products or companies described in this article.

How to cite: Eslamian L, Torshabi M, Motamedian SR, Hemmati YB, Mortazavi SA. The effect of naproxen patches on relieving orthodontic pain by evaluation of VAS and IL-1β inflammatory factor: a split-mouth study. Dental Press J. Orthod. 2019 Nov-Dec;24(6):27.e1-7.

DOI: https://doi.org/10.1590/2177-6709.24.6.27.e1-7
doi:10.1590/2177-6709.24.6.27.e1-7

Submitted: October 16, 2018 – Revised and accepted: March 07, 2019

Contact address: Yasamin Babae Hemmati Department of Orthodontics, School of Dentistry Guilan University of Medical Sciences, Fouman-Saravan Rd, Rasht, Iran E-mail: Yasi.10482@gmail.com
INTRODUCTION

One of the main concerns regarding orthodontic treatment is the pain associated to the tooth movement. This pain could be discouraging and considered as one of the reasons for not participating in orthodontic treatment process. About 77% to 95% of the patients in the orthodontic clinics have reported some degree of pain and discomfort. Orthodontic treatment-related pain could be initiated after four hours, reaches its peak after 12-72 hours and decrease to its baseline values after 7 days.

Some mechanisms have been proposed to explain the pain related to orthodontic tooth movement (OTM). Ischemic regions in the periodontal ligament (PDL) and mild transient pulpal inflammation are among these mechanisms. During OTM, some cytokines such as prostaglandins, substance P, histamine and leukotrienes are released and could cause pain.

Interleukin 1β (IL-1β) is an inflammatory mediator that can be released as a response to the substance P and is involved in bone remodeling process. IL-1β is produced in PDL during OTM, and can be found in gingival crevicular fluid (GCF). It has been demonstrated that rapid OTM using elastic separators could increase prostaglandin E2 level relative to severity of initial pain and increase IL-1β levels relative to severity of delayed pain.

Prostaglandins, which are inflammatory mediators necessary for OTM, are among probable pain stimulators. Therefore, inhibitors of prostaglandins such as non-steroidal anti-inflammatory drugs (NSAIDs) can be prescribed to alleviate pain of orthodontic treatment. Naproxen, which is available with Diocodal and Anaprox commercial names, is one of the NSAIDs that can prohibit production of prostaglandins and leukotrienes. Therefore, its efficacy in orthodontic pain management has been evaluated in some studies.

Although it has been reported that naproxen is an effective painkiller during OTM, its efficacy during local delivery as mucosal patches has not been studied.

Several medications and other approaches such as low level laser therapy, chewing gum, local prescription of gels and patches, vibratory and transcutaneous electric nerve stimulation have been introduced for pain control during orthodontic treatment; however, no general consensus has been reached. The most appropriate method should be efficient with minor or no harm for the patient. Therefore, the current study was performed to compare the efficacy of naproxen patches in pain control during orthodontic tooth separation, using the visual analogue scales (VAS) and IL-1β levels in GCF. Naproxen patches were used for local delivery of the drugs, in order to increase its efficiency as well as reducing the dosage of the drug and possible risks of systemic prescription.

MATERIAL AND METHODS

Study design

This triple blind split-mouth randomized controlled clinical trial was performed on patients referred to the orthodontic department (Shahid Beheshti University of Medical Sciences) for fixed orthodontic treatment in 2016. Study protocol was according to CONSORT statement 2010, and was approved by the ethical committee of the university. Also, informed consent was taken from all included patients.

Patients

Adult patients (age ≥ 18 years) who needed banding of upper first molars for fixed orthodontic treatment were enrolled consecutively from study population. The inclusion criteria were: generally healthy patients, no periodontal or endodontic disease, presence of bilateral first and second maxillary molars and second maxillary premolars, tight posterior teeth contacts with no spacing, presence of antagonist teeth without posterior open bite, and no psychologic or mental disorder. Patients who did not participate in the follow up sessions, had no pain on both sides, took systemic or topical painkillers except prescribed patches, removed separators, did not use patches as prescribed, and did not fill VAS questionnaire on time or lacked cooperation were excluded. The sample size of 23 was calculated to find 1 unit difference with 1.1 unit standard deviation between two groups and considering α=0.05, β=80%, Zα=1.96 and Zβ=0.84. Sample size was increased to 40 patients in order to increase study power and considering probable dropouts.

Preparation of naproxen patch

Naproxen patches were prepared using solvent casting method: 2.5% HPMC and 1% PVL were used for adhesion to the oral mucosa; also, 4% propylene glycol was used for ligation of naproxen, and 0.25% aspartame was used to sweeten the patches. Ingredients plus naproxen (South China pharmaceutical company, Shenzhen, China) were solved in chloromethane and alcohol solvents with 2:1 ratio and kept under fume hood for 72 hours. In order to evaporate the remaining solvents, the fabricated patches were dried for one more week in the room.
The proper size of the patches was determined following try and error method: 0.5 x 1.5-cm patches seemed to be the most appropriate size for adhesion and remaining in place.

**Tooth separation**

Two sets of patches were prepared and coded: one set contained 5% naproxen, and the other set without naproxen (placebo). The patches and their packages were visually similar and only a code was written on each package. So, neither the examiner nor the patient were aware of the type of the patches (double blind). Maxillary first molars were separated from adjacent teeth using elastic separators (American Orthodontics, Monrovia, CA, USA). One package of each set was given to the patient. Then, the patient was instructed to place one patch from one of the packages on the attached and free gingiva of maxillary first molar of one side and one patch from the other package on the other side molar. The sides were randomly selected using coin flip method. Patient’s age, gender as well as code of the patch used on each side were recorded. The patients were instructed to place the patch on the gingiva, press it and hold it for 20 seconds every 8 hours for 7 days. There was no limitation for eating and drinking. Also, the patients were instructed to use painkillers if they had intolerable pain.

**Outcome measurement: pain**

The patients were instructed to record the pain they felt on each side after 1 and 6 hours, at night, 24, 48 and 72 hours and 7 days, based on a 100-mm VAS ruler. A questionnaire including 21 VAS rulers and instruction were given to the patients. Zero indicated no pain, while 100 showed the most severe pain.

**Outcome measurement: IL-1β**

Levels of IL-1β in GCF was measured at the time of tooth separation (baseline) and after 1 and 24 hours and 7 days, using ELISA. First, GCF was collected from distobuccal and mesiobuccal sulcus of maxillary first molars using paper cones (ARIA DENT Tehran, Iran) size 30 after isolation with cotton roll. For this, paper cones were inserted 1 mm into gingival sulcus for 60 seconds. Then, paper cones were transferred to sterile 1.5-ml µtubes containing 200 µl phosphate buffered saline for couple of minutes followed by 10-minute centrifugation at 3000 rpm at 4°C. Finally, the supernatant fluid containing GCF proteins was transferred to another sterile µtube, which was frozen at -70°C.

Commercial ELISA kit (GMBH, Berlin, Germany) was used to measure the levels of IL-1β in the GCF samples, following manufacturer’s instructions. Briefly, the kit micro-wells including human anti-IL were rinsed twice with 400 µl PBS. Then, 50 µl buffer and 50 µl of each sample plus 50 µl Biotin-conjugated anti-human IL added to each well and incubated for 2 hours at room temperature. The wells were rinsed 3 times and received 100 µl Streptavidin-HRP enzyme and incubated one more hour. Again, the wells were rinsed and 100 µl substrate was added to each well and incubated for 10 minutes. Finally, 100 µl stop solution was added to each well and color to the wells containing IL, which turned yellow. Optical density was read using ELISA reader (Anthos2020, Berlin, Germany) at 450 wavelengths. Finally, density of IL-1β (pg/ml) was determined using standard absorbance values (Fig. 1).

**Statistical analysis**

The results of pilot study were compared using repeated measure ANOVA. A two-way repeated measure ANOVA was used to analyze the effect of study group, time, as well as pain scores or levels of IL-1β. To compare patients pain scores or IL-1β levels at each time point between the two groups, paired samples t-test was applied. To evaluate association of pain scores and levels of IL-1β, Pearson correlation coefficient and regression model was used.

All statistical analyses were performed using SPSS computer software (SPSS Inc., Chicago, IL, USA), with a significance level of 0.05, by an expert who was blind to the allocated groups (triple blind).

**RESULTS**

A total of 40 patients (23 females and 17 males) were enrolled in the study, out of which 10 patients were excluded. The reasons for exclusion were: no regular use of the patches (2 patients), lack of pain at both sides (7 patients) and use of painkiller during the experiment (1 patient). Therefore, a final number of 30 patients (13 males and 17 females) with a mean age of 27.47±4.08 years (22 to 40 years) finished the study.

**Pain**

The mean and standard deviation (±SD) of pain scores based on VAS at different time points in both groups are shown in Table 1. Two-way repeated measure ANOVA revealed that groups (naproxen vs. placebo) (p<0.0001), time (p<0.0001) and their interaction (p=0.005) had a
The effect of naproxen patches on relieving orthodontic pain by evaluation of VAS and IL-1β inflammatory factor: a split-mouth study

Significant effect on the pain scores. Comparison of the mean pain scores at each time point between two groups revealed significantly lower pain score at naproxen group at each time point ($p<0.05$) except at 1 hour after separation ($p=0.792$).

There was no difference in the mean pain scores between males and females ($p=0.29$).

**Level of IL-1β**

The mean and standard deviation of levels of IL-1β at different time points in both groups are demonstrated in Table 2. Two-way repeated measure ANOVA revealed that groups (naproxen vs. placebo) ($p=0.047$), time ($p<0.0001$) had a significant effect on the levels of IL-1β. However, their interaction was not statistically significant ($p=0.3$). Comparison of mean levels of IL-1β at each time point between two groups revealed that only 1 hour after separation naproxen group had significantly lower levels of IL-1β, compared to placebo group; while the difference at other time points was not significant ($p>0.05$).

There was no difference in the mean IL-1β levels between males and females ($p=0.92$).

**Association of pain and level of IL-1β**

Pearson correlation coefficient showed significant positive correlation between pain scores and IL-1β levels in control group after 1 hour ($p=0.04$ and $r=0.374$) and a negative correlation between them in naproxen group after 7 days ($p=0.03$ and $r=-0.395$) (Table 3).

Linear regression model revealed that each 10 unit increase in IL-1β levels is related to 2 unit increase in the pain scores. Therefore, the following formula could be used to show correlation between pain scores and IL-1β levels: Pain (VAS) = 1 ± 0.2 IL-1β (pg/ml)

**Table 1** - Comparison of the mean pain scores at different time point between naproxen and placebo patch groups (sample size: 30).

| Group   | Time point | 1h     | 6h     | At night | 24h     | 2nd day at 6pm | 48h     | 72h     | 7 days |
|---------|------------|--------|--------|----------|---------|----------------|---------|---------|--------|
| Placebo | Mean       | 17.67  | 27.83  | 32.17    | 36.50   | 32.00          | 26.83   | 21.67   | 14.50  |
|         | SD         | 14.840 | 20.286 | 21.483   | 23.087  | 20.536         | 18.959  | 18.770  | 17.40  |
| Naproxen| Mean       | 18.17  | 21.33  | 26.00    | 27.33   | 23.50          | 18.17   | 15.67   | 10.33  |
|         | SD         | 16.891 | 17.267 | 18.213   | 20.331  | 18.059         | 14.650  | 14.126  | 9.820  |
| P value |            | 0.792  | < 0.001*| < 0.001* | < 0.001*| < 0.001*       | < 0.001*| < 0.001*| < 0.026*|

* Significant at 0.05 using paired samples t-test.

**Table 2** - Comparison of the mean IL-1β levels at different time points between naproxen and placebo patch groups (sample size: 30).

| Group   | Time point | baseline | 1h     | 24h     | 7 days |
|---------|------------|----------|--------|---------|--------|
| Placebo | Mean       | 68.69    | 87.83  | 102.66  | 74.18  |
|         | SD         | 4.33     | 5.34   | 7.17    | 5.48   |
| Naproxen| Mean       | 72.37    | 74.22  | 93.20   | 64.67  |
|         | SD         | 5.37     | 5.18   | 5.21    | 4.64   |
| P value |            | 0.552    | 0.047* | 0.253   | 0.115  |

* Significant at 0.05 using paired samples t-test.

**Table 3** - Association of pain scores and IL-1β levels in naproxen and placebo patch groups (sample size: 30).

| Group   | Time point | 1h     | 24h     | 7 days |
|---------|------------|--------|---------|--------|
| Placebo | Pearson Correlation | 0.374 | 0.04 | 0.015 |
|         | P value    | 0.04*  | 0.83   | 0.94   |
| Naproxen| Pearson Correlation | 0.077 | 0.144 | 0.395 |
|         | P value    | 0.69   | 0.45   | 0.03*  |

* Significant at 0.05.
DISCUSSION

NSAIDs are appropriate choices for pain management during orthodontic treatment, as the pain is related to combination of pressure, ischemia and inflammation.23,24 The current study was performed to evaluate the effect of naproxen patch on separator placement pain relief. The results revealed that patients felt less severe pain on the side that received naproxen patch, compared to the placebo side, at every time point, except 1 hour after tooth separation.

NSAIDs could have various complications25,26 such as gastrointestinal problems.27 They inhibit cyclooxygenase enzyme and reduce production of prostaglandins, which have a preservative role in gastrointestinal mucosa. Therefore, their administration should be limited. The current study evaluated the effectiveness of local delivery of naproxen in order to reduce systemic complications. Locally administered naproxen was used in a recent study by Eslamian et al.14 The naproxen gel which they used have several limitations such as rapid wash out by saliva and various dosage while applying the gel on the desired site. The naproxen patches used in the current study could release the drug up to 2 hours after application and had exactly the same dosage of naproxen, as they all had the same size. Although variety in gingival thickness could cause different levels of drug absorption released from patches, the split-mouth design was applied to reduce the effect of this possible confounding factor.

Comparison of mean pain scores between the two groups showed significantly lower pain in the naproxen group at every time point, except 1 hour after separation. These results are in agreement with some previous studies.14-17,28 Eslamian et al.14 evaluated the effectiveness of 5% naproxen gel administered every 8 hours for 3 days on pain management related to elastic separators in a split-mouth study. They concluded that naproxen gel significantly reduced pain scores assessed by VAS at every time point from 1 hour to 7 days. Two studies by Polat et al.16,17 showed that single dose naproxen was able to decrease the pain of fixed archwire activation and it was more effective that other analgesics during the first day. However, Patel et al.15 reported that administration of naproxen 1 hour before and 3 and 7 hours after separation did not significantly reduce patients’ pain. A recent systematic review reported that naproxen has a significant effect in OTM pain relieve at 6, 12, and 24 hours.28 The cited review also concluded that the timing of administration could significantly influence the effectiveness of naproxen.

The results of the current study showed that the mean pain score in both groups reaches its peak after 24 hours and then decrease until 7 days. It seems that the most prominent inflammatory responses during OTM happen during the first day.29,30 Previous studies also reported highest pain after 24 hours.17,23,31-33 Also, similar to the previous studies,14,15,19,34,35 there was no significant difference between pain experienced by males and females in this study.
The pain model and assessment of pain using VAS are common methods in orthodontic literature. Placement of elastic separators move the teeth and can cause various degrees of pain. Compared to archwire activation, placement of separators allows more control on the confounding factors. The VAS also have been demonstrated to have an acceptable precision and validity for assessment of subjective pain and could be used for comparison of pain between groups.

It has been revealed that IL-1 levels increase during experimental tooth movement, reaching its peak after 1 day and recovering to the normal value during 1 week. Also, previous human studies showed up-regulation of IL-1 after 24 hours during OTM. Since the peak pain intensity and IL-1 level during OTM occurs simultaneously after 24 hours, in the current study the level of IL-1 was considered as an indicator of pain intensity. However, Gameiro et al. reported that IL-1 levels and pain scores were not statistically correlated at every time point. The results showed that, similar to the previous studies, levels of IL-1 reached its peak after 24 hours, at which the pain scores were also at their highest level. However, statically significant but weak correlation between levels of IL-1 and the pain score was found only at 1 hour after separator placement in the control group and after 7 days in the naproxen group. Lack of correlation between IL-1 level and pain score might be the reason for non-significant difference in IL-1 levels between the two groups after 1 and 7 days. Gameiro et al. stated that IL-1 could not be used as the sole measurement for assessment of pain during OTM. Future studies should assess levels of other cytokines in GCF to find the one that have stronger correlation with pain intensity.

CONCLUSION

The pain scores in the naproxen group were lower than placebo groups at all time points from 6 hours to 7 days after separation. However, the difference was not significant after 1 hour.

Levels of IL-1β was lower in naproxen group at 1 hour after separation, but no difference was found at later time points until 7 days. Lack of strong correlation between pain scores and IL-1 levels indicates that there is a need for other biologic indicators of pain intensity during OTM.

As the highest pain intensity was recorded one day after separation and naproxen patches were effective in pain relief, it could be concluded that naproxen patches could be administered specially at the first days after orthodontic separator placement.

This study showed that locally administered naproxen patches with lessened dosage can successfully relief pain and there is no need for systemic usage of the drug.

Acknowledgements

This work was funded by Dentofacial Deformities Center (Grant number 8478), Research Institute of Dental Sciences, Shahid Beheshti University of Medical Sciences.

Author’s contribution (ORCID)

Ladan Eslamian (LE): 0000-0002-3877-5560
Maryam Torshabi (MT): 0000-0003-4827-0942
Saeed Reza M. (SRM): 0000-0001-7337-2145
Yasamin B. Hemmati (YBH): 0000-0002-6739-9971
Seyed A. Mortazavi (SAM): 0000-0002-4027-620X

Conception or design of the study: LE, YBH. Data acquisition, analysis or interpretation: LE, MT, SRM, YBH, SAM. Writing the article: SRM, YBH. Critical revision of the article: LE, MT, SRM, YBH, SAM. Final approval of the article: LE, MT, SRM, YBH, SAM. Obtained funding: LE. Overall responsibility: LE, MT, SRM, YBH, SAM.
REFERENCES

1. Firestone AR, Scheuer PA, Burgin WB. Patients’ anticipation of pain and pain-related side effects, and their perception of pain as a result of orthodontic treatment with fixed appliances. Eur J Orthod 1999;21:387-96.

2. Vachiramon A, Wang WC. Acupuncture and acupressure techniques for reducing orthodontic post-adjustment pain. J Contemp Dent Pract. 2005 Feb 15;6(1):163-7.

3. Oliver RG, Knappan YM. Attitudes to orthodontic treatment. Br J Orthod. 1985 Oct;12(4):179-88.

4. Feldmann I, List T, Bondemark L. Orthodontic anchoring techniques and its influence on pain, discomfort, and jaw function—a randomized controlled trial. Eur J Orthod. 2012 Feb;34(1):102-8.

5. Johal, A, Fleming PS, Al Jawad FA. A prospective longitudinal controlled assessment of pain experience and oral health-related quality of life in adolescents undergoing fixed appliance treatment. Orthod Craniofac Res. 2014 Aug;17(3):178-86.

6. Eslamipour F, Motamedian SR, Bagheri F. Ibuprofen and low-level laser therapy for pain control during fixed orthodontic therapy: a systematic review of randomized controlled trials and meta-analysis. J Contemp Dent Pract. 2017 Jun 1;18(6):527-33.

7. Norevall LI, Forsgren S, Mattson S. Expression of neuropeptides (CGRP, substance P) during and after orthodontic tooth movement in the rat. Eur J Orthod. 1995 Aug;17(4):311-25.

8. Stanfeld J, Jones J, Laster L, Davidovitch Z. Biochemical aspects of orthodontic tooth movement. I. Cyclic nucleotide and prostaglandin concentrations in tissues surrounding orthodontically treated teeth in vivo. Am J Orthod Dentofacial Orthop. 1986 Aug 90(2):139-48.

9. Uematsu S, Mogi M, Deguchi T. Interleukin (IL)-1 beta, IL-6, tumor necrosis factor-alpha, epidermal growth factor, and beta 2-microglobulin levels are elevated in gingival crevicular fluid during human orthodontic tooth movement. J Dent Res. 1996 Jan;75(1):562-7.

10. Lee, KJ, Park YC, Yu HS, Choi SH, You YJ. Effects of continuous and interrupted orthodontic force on interleukin-1beta and prostaglandin E2 production in gingival crevicular fluid. Am J Orthod Dentofacial Orthop. 2004 Feb;125(2):168-77.

11. Giannopoulou C, Dutc D, Killaridis S. Pain discomfort and crevicular fluid changes induced by orthodontic elastic separators in children. J Pain. 2006 May;7(5):367-76.

12. Mehlisch DR, Sollecito WA, Helrich JF, Leibold DG, Markowitz R, Schow CE, Jr, et al. Multicenter clinical trial of ibuprofen and acetaminophen in the treatment of postoperative dental pain. J Am Dent Assoc. 1990 Aug;121(2):257-63.

13. Roda RS. Naproxen: pharmacology and dental therapeutics. J Can Dent Assoc. 1992 May;58(5):401-5.

14. Eslamian L, Kianpour A, Mortazavi SAR. The analgesic efficacy of 5% naproxen gel for pain associated with orthodontic separator placement: a randomized double-blind controlled trial. Anesth Pain Med. 2017 Apr;7(2):e24708.

15. Patel S, McGorray SP, Yezierski R, Fillingim R, Logan H, Wheeler TT. Effects of analgesics on orthodontic pain. Am J Orthod Dentofacial Orthop. 2011 Jan;139(1):e53-8.

16. Polat O, Karaman AI. Pain control during fixed orthodontic appliance therapy. Angle Orthod. 2005 Mar;75(2):214-9.

17. Polat O, Karaman AI, Durmus E. Effects of preemptive ibuprofen and naproxen sodium on orthodontic pain. Angle Orthod. 2005 Sep;75(3):791-6.

18. Xiaoting L, Yin T, Yangxi C. Interventions for pain during fixed orthodontic appliance therapy: a systematic review. Angle Orthod. 2010 Sept-Oct;80(5):925-32.

19. Eslamian L, Borzabadi-Farahani A, Edini HZ, Badiee MR, Lynch E, Mortazavi A. The analgesic effect of benzocaine mucoadhesive patches on orthodontic pain caused by elastomeric separators, a preliminary study. Acta Odontol Scand. 2013 Sept;71(5):1168-73.

20. Eslamian L, Borzabadi-Farahani A, Gholami H. The effect of benzocaine and ketoprofen gels on pain during fixed orthodontic appliance treatment: a randomised, double-blind, crossover trial. Aust Orthod J. 2016 May;32(1):64-72.

21. Eslamian L, Borzabadi-Farahani A, Hassanzadeh-Azrini A, Badiee MR, Fekrazad R. The effect of 810-nm low-level laser therapy on pain caused by orthodontic elastomeric separators. Lasers Med Sci. 2014 Mar;29(2):559-64.

22. Eslamian L, Gholami H, Mortazavi SA, Soheilifar S. Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double-blind randomized controlled trial. Orthod Craniofac Res. 2016 Nov;19(4):190-7.

23. Bernhardt MK, Southard KA, Batterson KD, Logan HL, Baker KA, Jakobsen JR. The effect of preemptive and/or postoperative ibuprofen therapy for orthodontic pain. Am J Orthod Dentofacial Orthop. 2001 Jul;120(1):20-7.

24. Stein Law SL, Southard KA, Law AS, Logan HL, Jakobsen JR. An evaluation of preemptive ibuprofen for treatment of pain associated with orthodontic separator placement. Am J Orthod Dentofacial Orthop. 2000 Dec;118(6):629-35.

25. Fanelli, A, Romualdi P, Vigano R, Lora Aprile P, Gensini G, Fanelli G. Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. Acta Biomed. 2013 Jun 1;84(1):5-11.

26. Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs). BMJ 2013;346:f1395.

27. Rafaeielo C, Ferrajolo C, Sullo MG, Sessa M, Sportello L, Balzano A, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res. 2016 Feb;104:108-14.

28. Sandhu SS, Peploe HP, Rethera HS. Comparing the effectiveness profile of pharmacological interventions used for orthodontic pain relief: an arm-based multilevel network meta-analysis of longitudinal data. Eur J Orthod. 2017 Nov 30;39(6):601-14.

29. Turhani D, Schenkau M, Kapral D, Benesch T, Jonke E, Bantleon HP. Pain relief by single low-level laser irradiation in orthodontic patients undergoing fixed appliance therapy. Am J Orthod Dentofacial Orthop. 2006 Sep;130(3):371-7.

30. Tortamano A, Lenzic DC, Haddad AC, Bottino MC, Dominguez GC, Vigorito JW. Low-level laser therapy for pain caused by placement of the first orthodontic archwire: a randomized clinical trial. Am J Orthod Dentofacial Orthop. 2009 Nov;136(5):662-7.

31. Luppenapornlarp S, Kajii TS, Surarit R, Iida J. Interleukin-1beta levels, pain intensity, and tooth movement using two different magnitudes of continuous orthodontic force. Eur J Orthod. 2010 Oct;32(5):396-601.

32. Gamein GH, Schultz C, Trein MP, Mundstock IS, Wiedlich P, Goularte JF. Association among pain, masticatory performance, and proinflammatory cytokines in crevicular fluid during orthodontic treatment. Am J Orthod Dentofacial Orthop. 2015 Dec;148(6):967-73.

33. Klueper GT, Higer DG, Rayens MK, Jay MJ. Efficacy of a wax containing benzocaine in the relief of oral mucosal pain caused by orthodontic appliances. Am J Orthod Dentofacial Orthop. 2002 Oct;122(4):359-65.

34. Minor V, Marris CK, McGorray SP, Yezierski R, Fillingim R, Logan H, et al. Effects of preemptive ibuprofen on pain after separator placement. Am J Orthod Dentofacial Orthop. 2009 Oct;136(4):510-7.

35. Pringle AM, Petrie A, Cunningham SJ, McKnight M. Prospective randomized clinical trial to compare pain levels associated with 2 orthodontic fixed bracket systems. Am J Orthod Dentofacial Orthop. 2009 Aug;136(2):160-7.

36. Bergius M, Killaridis S, Berggren U. Pain in orthodontics. A review and discussion of the literature. J Orofac Orthop. 2000;61(2):125-37.

37. Otsavec M, Nairn FB, Gill DS, Lee RT. Prospective randomized clinical trial comparing the effects of a masticatory bite wafer and avoidance of hard food on pain associated with initial orthodontic tooth movement. Am J Orthod Dentofacial Orthop. 2006 July;130(1):e9-15.

38. Sriwatanakul K, Kelvie W, Lasagna L, Calmimi JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther. 1983 Aug;34(2):234-9.

39. Gracely, RH, McGrath F, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain. 1978 June;5(1):5-18.

40. Horinuki E, Yamamoto K, Shimizu N, Koshikawa N, Kobayashi M. Sequential changes in the sensory and affective dimensions of experimental pain. J Pain Pract. 2017 Jun 1;18(6):527-33.